Dexcom on Monday announced its new over-the-counter continuous glucose monitor Stelo is officially available for purchase in the U.S.
Glucose is a type of sugar people receive from food, and it’s the body’s main source of energy. Continuous glucose monitors, or CGMs, are small sensors that poke through the skin to measure glucose levels in real time. They are typically prescribed to patients with diabetes since they can help alert users, their loved ones and their doctors to emergencies.
Stelo is primarily intended for patients with prediabetes or Type 2 diabetes who do not use insulin, though individuals without either condition can also purchase it. Users can buy a one-month supply online for $99, or sign up for an ongoing subscription at $89 a month.
Dexcom said patients also have the option to use their flexible spending accounts and health savings accounts to pay for Stelo, according to a statement.
The company already offers continuous glucose monitors for Type 1 and Type 2 diabetes patients, but Stelo is Dexcom’s first product that does not require a prescription. While most Type 1 patients can already get insurance coverage for the sensors, Stelo is now accessible to millions of Type 2 patients who have been unable to get prescriptions or coverage. It also marks the company’s official foray into a new and potentially lucrative prediabetes market.
Dexcom said there are more than 125 million Americans with prediabetes or Type 2 diabetes not using insulin, according to a statement. The company designed Stelo to help teach this patient population how to keep their glucose levels within a healthy range.
“The idea is to help people, over time, learn about diet choices and habits, and how those are impacting glucose,” Jake Leach, chief operating officer at Dexcom, told CNBC in an interview. “It’s about uncovering things you haven’t seen before and then using that to create healthier habits.”
How it works
The U.S. Food and Drug Administration approved Stelo in March. It was the first over-the-counter continuous glucose monitor to be cleared for use, though Dexcom’s competitor, Abbott, received clearance for two similar devices in June.
Leach said Dexcom is working with Amazon to fulfill Stelo deliveries. Users with a subscription can choose to skip or adjust their delivery date, but it will typically be scheduled at the 30-day interval from their initial sign-up.
Stelo is worn on the upper arm and lasts for 15 days before it needs to be replaced. It’s gray, about the size of a quarter and around half an inch thick.
The sensor wirelessly transmits data to a smartphone app. When users are getting set up, they’ll select whether they have Type 2 diabetes, prediabetes or none of the above. This helps establish their “Target Range,” which is where Dexcom wants users to try and keep their glucose levels. The target range is based on established medical standards, and most people fall between 70 and 180 milligrams per deciliter, according to the American Diabetes Association.
When they open the Stelo homepage, they’ll see their latest reading, which is updated every 15 minutes. They’ll also see a graph of their readings each day, which includes a shaded green area to indicate the target range. If they scroll down, they’ll see a summary of the time spent in the target range over time.
Everyone’s glucose levels are variable, but Stelo will send users a notification when they are experiencing a substantial spike. Glucose spikes occur when the amount of sugar present in the bloodstream rapidly increases and then decreases. This often happens after eating.
In the short term, spikes can cause feelings of fatigue, but high glucose levels can lead to more serious health problems like diabetes, heart disease and kidney disease over time, according to the Centers for Disease Control and Prevention. This is why Dexcom wants users to try and keep their levels within Stelo’s target range.
The tab next to the home page is the “Events” page, which is where Stelo users can log meals, activity, fingersticks or other notes. Leach said it’s most important for users to log an entry when they’re experiencing a big spike so that they can reflect on what might be causing it.
Stelo notifies users about noteworthy spikes, so they won’t necessarily get alerted every time their levels rise. Leach said this is an intentional design choice that’s meant to call attention to the larger swings that patients experience.
“Even for someone who has normal glucose and the occasional spike, it’ll look for the most impactful spikes and then try to engage the user around, ‘OK, what happened there?'” he said.
And for users who want to dig deeper into their glucose and understand what causes spikes, there’s a trove of educational materials in the app’s “Learn” tab. The articles are brief, sometimes only a few sentences, and they’re broken down into categories like “Stelo Basics,” “Glucose Deep Dive,” “Nutrition,” “Exercise,” “Sleep” and “Stress.”
CNBC Tests Stelo
The Stelo app
Courtesy of Dexcom
I’ve been testing Stelo since early August. On the whole, I think it’s been easy and helpful to use.
When my monitors arrived in the mail, the first order of business was applying the sensor to my arm and pairing it with the Stelo app. I found this process very straightforward – the app walked me through what to do with clear, step-by-step instructions.
I cleaned the back of my right arm, placed Dexcom’s applicator there, pressed the button and popped the CGM right on. It happens fast and doesn’t hurt at all.
The monitor connects to the Stelo app via Bluetooth, and then it takes about a half hour to warm up.
This is where I initially encountered some problems. Once my device had warmed up, I got an error message that said “Brief Sensor Issue.” The message told me not to take off the CGM, and that the issue was temporary. I left it on for the day, but by evening, I noticed some light bleeding. I decided to take that sensor off.
I applied another CGM to my other arm, and that one warmed up and worked correctly. I’ve been wearing it ever since and haven’t had any trouble with bleeding. Leach said if users have problems with the product, they can message the chat interface on Stelo’s website to get a replacement or answer their questions there.
Once I was all up and running with my second sensor, it was smooth sailing.
I’ve found the Stelo app simple and easy to use. I never feltlike I was being overloaded with too much data or too many notifications, and logging meals and exercise is very straightforward. Users can also choose to import their sleep and activity data from the Apple Health app or Android’s Health Connect app, which I think is a nice touch.
If it’s your first time using a CGM, I definitely recommend reading through the articles in the “Learn” tab. I think Dexcom does a good job using plain language to explain what glucose is, what affects it and why it matters.
The longer I wear the sensor, the more I can tell that the algorithm is tuning to me and my habits. I don’t get notifications each time my glucose spikes, but it does alert me when I’m experiencing a particularly substantial jump. The app is also beginning to pick up on my patterns. For instance, it recently told me that my glucose tends to spike between 5 p.m. and 7 p.m., which is usually around when I eat dinner.
Most of the time, I forget I’m even wearing a sensor. It’s waterproof, so I didn’t need to worry about it in the shower. And I didn’t notice it when I was sleeping. I’d advise a little caution when pulling on long sleeves, as the sensor can snag a bit, but it’s easy to wear all types of clothes and jackets over it.
In the short time I’ve been using Stelo, I’ve learned a lot about how my body responds to certain foods. Even small adjustments (eating carbs last, for instance) helped me reduce spikes. It’s easy to see how CGMs can serve as a valuable window into the body. If you’re looking for a simple, approachable entry to understanding your glucose data, I think Stelo is a solid option.
The Hers app arranged on a smartphone in New York, US, on Wednesday, Feb. 12, 2025.
Gabby Jones | Bloomberg | Getty Images
Shares of Hims & Hers Health fell 9% in extended trading on Monday after the telehealth company reported second-quarter results that missed Wall Street’s expectations for revenue.
Here’s how the company did based on average analysts’ estimates compiled by LSEG:
Earnings per share: 17 cents adjusted vs. 15 cents
Revenue: $544.8 million vs. $552 million
Revenue at Hims & Hers increased 73% in the second quarter from $315.6 million during the same period last year, according to a release. Hims & Hers reported a net income of $42.5 million, or 17 cents per share, compared to $13.3 million, or 6 cents per share, during the same period a year earlier.
For its third quarter, Hims & Hers said it expected to report revenue between $570 million to $590 million, while analysts were expecting $583 million. The company said its adjusted EBITDA for the quarter will be between the range of $60 million to $70 million. Analysts polled by StreetAccount were expecting $77.1 million.
Read more CNBC tech news
Hims & Hers has faced controversy in recent months over its continued sale of compounded GLP-1s, which are cheaper, unapproved versions of the blockbuster diabetes and weight loss drugs. Compounded drugs can be mass produced when brand-name treatments are in shortage, but the U.S. Food and Drug Administration announced in February that ongoing supply issues had been resolved.
Some telehealth companies, including Hims & Hers, have continued to offer the compounded medications. It’s legal for patients to access personalized doses of the knockoffs in unique cases, like if they are allergic to an ingredient in a branded product, for instance. Hims & Hers has said consumers may still be able to access personalized doses through its site if clinically applicable.
In June, Hims & Hers shares tumbled more than 30% after a short-lived collaboration with Novo Nordisk fell apart. The drugmaker said Hims & Hers “failed to adhere to the law which prohibits mass sales of compounded drugs” under the “false guise” of personalization.
Hims & Hers reported adjusted EBITDA of $82 million for its second quarter, up from $39.3 million last year and above the $73 million expected by StreetAccount.
Hims & Hers will host its quarterly call with investors at 5 p.m. ET.
Stock Chart IconStock chart icon
YTD chart of Hims & Hers Health.
–CNBC’s Annika Kim Constantino contributed to this report
Palantir topped Wall Street’s estimates Monday, surpassing $1 billion in quarterly revenue for the first time, and hiking its full-year guidance.
Shares rallied more than 5%.
Here’s how the company did versus LSEG estimates:
Earnings per share: 16 cents adj. vs. 14 cents expected
Revenue: $1.00 billion vs. $940 million expected
The artificial intelligence software provider’s revenues grew 48% during the period. Analysts hadn’t expected the $1 billion revenue benchmark from the Denver-based company until the fourth quarter of this year.
“The growth rate of our business has accelerated radically, after years of investment on our part and derision by some,” wrote CEO Alex Karp in a letter to shareholders. “The skeptics are admittedly fewer now, having been defanged and bent into a kind of submission.”
The software analytics company also boosted its full-year outlook guidance. For the full year, Palantir now expects revenues to range between $4.142 billion and $4.150 billion, up from prior guidance of $3.89 billion to $3.90 billion.
Read more CNBC tech news
For the third quarter, Palantir forecast revenues between $1.083 billion and $1.087 billion, beating an analyst estimate of $983 million. Palantir also lifted its operating income and full-year free cash flow guidance.
Palantir’s U.S. revenues jumped 68% from a year ago to $733 million, while U.S. commercial revenues nearly doubled from a year ago to $306 million.
The software analytics company has seen a boost from President Donald Trump‘s government efficiency campaign, which included layoffs and contract cuts. Palantir’s U.S. government revenues jumped 53% from the year-ago period to $426 million.
“It has been a steep and upward climb — an ascent that is a reflection of the remarkable confluence of the arrival of language models, the chips necessary to power them, and our software infrastructure,” Karp wrote in a letter to shareholders.
During the quarter, Palantir said it closed 66 deals of at least $5 million and 42 deals totaling at least $10 million. Total value of its contracts grew 140% from last year to $2.27 billion.
Net income rose 144% to about $326.7 million, or 13 cents a share, from about $134.1 million, or 6 cents per share a year ago.
Palantir shares have more than doubled this year as investors bet on the company’s AI tools and contract agreements with governments.
Its market value has accelerated past $379 billion and into the list of top 20 most valuable U.S companies, surpassing Salesforce, IBM and Cisco to join the top 10 U.S. tech companies by market cap. Shares hit a new high Monday.
At its size, buying the stock requires investors to pay hefty multiples.
Shares currently trade 276 times forward earnings, according to FactSet. Tesla is the only other top 20 with a triple-digit ratio at 177.
Firefly Aerospace CEO Jason Kim sits for an interview at the Firefly Aerospace mission operations center in Leander, Texas, on July 9, 2025.
Sergio Flores | Reuters
Firefly Aerospace has lifted the share price range for its upcoming initial public offering in a move that would value the space technology company at more than $6 billion.
The lunar lander and rocket maker said in a filing Monday that it expects to price shares in its upcoming IPO between $41 and $43 apiece.
Firefly’s new target range would raise nearly $697 million at the top end of the range. That’s up from the previously expected $35 to $39 price per share that Firefly announced in a filing last week, which targeted a $5.5 billion valuation.
Firefly announced plans to go public last month as interest in space technology gains steam, and billionaire-led companies such as Elon Musk‘s SpaceX rake in more funding.
Read more CNBC tech news
The industry has also begun testing the public markets after a long hiatus in IPO deal activity, with space tech firm Voyager debuting in June.
Firefly makes rockets, space tugs and lunar landers, and is widely known for its satellite launching rockets known as Alpha.
The company has partnered with major defense players such as Lockheed Martin, L3Harris and NASA, and received a $50 million investment from defense contractor Northrop Grumman.
Firefly’s revenues jumped from $8.3 million a year ago to $55.9 million at the end of March, the company said. Its net loss grew to $60.1 million, from $52.8 million a year ago.